A Multicentre, Retrospective Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Study to Evaluate the Outcome of HSCT Mismatch Unrelated Donors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04598789

Enrollment

Registered

2020-10-22

Start date

2020-07-07

Completion date

2021-09-01

Last updated

2021-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia, Myeloid

Brief summary

The primary endpoint of the study was the acute GvHD incidence, the secondary endpoints were chronic GvHD incidence, overall survival (OS), transplant related mortality (TRM) incidence, relapse incidence (RI) and neutrophil and platelets engraftment after GvHD prophylaxis with ATG-CSA-MTX or PTCy-MMF-FK506

Interventions

OTHERno intervention

no intervention, observational study

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* children and adults) * HSCT from a one-antigen mismatch unrelated donors * Treated at the Centro Trapianti Metropolitano di Torino between 2012 to 2017

Exclusion criteria

none

Design outcomes

Primary

Measure	Time frame
acute GvHD incidence	2012-2017

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026